Association between low-density lipoprotein cholesterol level and all-cause mortality in idiopathic dilated cardiomyopathy patients: a single-institutional study

Abstract Aims To determine the association between all-cause mortality and low-density lipoprotein cholesterol (LDL-C) in patients with idiopathic cardiomyopathy (iDCM). Background LDL-C had long been considered as a dangerous predictor of cardiovascular diseases; however, the correlation between them was not fully clarified. Methods A total of 1058 patients who met the World Health Organization criteria for iDCM in West China Hospital (2009–2016) were enrolled in this retrospective study. Baseline demographic characteristics and correlations between variables were calculated and analyzed, and potential predictors were explored using univariate and multivariate regressions. Cox proportional hazards models were used to determine correlation on a continuous scale. Results LDL-C is an independent prognostic factor and higher LDL-C levels are associated with better prognosis in iDCM patients according to cox regression analysis. Compared with individuals which LDL > 2.28 mmol/L (75th–100th percentile), the multivariable-adjusted hazard ratio for all-cause mortality was 1.52 (95%CI: 1.03–2.26) in patients with LDL-C < 1.78 mmol/L (0–25th percentile). In patients with New York Heart Association function III and IV, LDL-C levels have a hazard ratio of 0.83 (confidence interval 0.73–0.95). Conclusions In patients with iDCM, lower LDL-C level was associated with an increased risk of all-cause mortality. The correlation between mortality and LDL-C level was stronger in patients with worse heart function. LDL-C levels have a potential predictive value in iDCM patients.

[1]  T. Minamino,et al.  The Prognostic Value of B‐Type Natriuretic Peptide in Patients With Cardiac Sarcoidosis Without Heart Failure: Insights From ILLUMINATE‐CS , 2022, Journal of the American Heart Association.

[2]  B. Nordestgaard,et al.  Association between low density lipoprotein and all cause and cause specific mortality in Denmark: prospective cohort study , 2020, BMJ.

[3]  T. Hohlfeld,et al.  Lipid lowering therapy in cardiovascular disease: From myth to molecular reality. , 2020, Pharmacology & therapeutics.

[4]  T. Strandberg,et al.  Mortality and Cholesterol Metabolism in Subjects Aged 75 Years and Older: The Helsinki Businessmen Study , 2020, Journal of the American Geriatrics Society.

[5]  Jiyan Chen,et al.  The prognostic nutritional index might predict clinical outcomes in patients with idiopathic dilated cardiomyopathy. , 2019, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[6]  M. Khan,et al.  Association of baseline LDL-C with total and cardiovascular mortality in patients using proprotein convertase subtilisin-kexin type 9 inhibitors: A systematic review and meta-analysis. , 2019, Journal of clinical lipidology.

[7]  M. Milošević,et al.  CHOLESTEROL AND CHLORIDE IN ACUTE HEART FAILURE , 2019, Acta clinica Croatica.

[8]  M. Schmitt,et al.  Towards cardiac MRI based risk stratification in idiopathic dilated cardiomyopathy , 2018, Heart.

[9]  Jennifer G. Robinson,et al.  Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis , 2018, JAMA.

[10]  Lale Tokgözoğlu,et al.  Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel , 2017, European heart journal.

[11]  J. Nunes Statins and the cholesterol mortality paradox , 2017, Scottish medical journal.

[12]  S. Cook,et al.  The Diagnosis and Evaluation of Dilated Cardiomyopathy. , 2016, Journal of the American College of Cardiology.

[13]  D. Diamond,et al.  Lack of an association or an inverse association between low-density-lipoprotein cholesterol and mortality in the elderly: a systematic review , 2016, BMJ Open.

[14]  U. Tietge Hyperlipidemia and cardiovascular disease: inflammation, dyslipidemia, and atherosclerosis. , 2014, Current opinion in lipidology.

[15]  Tevfik F Ismail,et al.  The Prevalence and Prognostic Significance of Right Ventricular Systolic Dysfunction in Nonischemic Dilated Cardiomyopathy , 2013, Circulation.

[16]  P. Reaven,et al.  Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretins , 2011, Cardiovascular diabetology.

[17]  P. Schnohr,et al.  Nonfasting cholesterol and triglycerides and association with risk of myocardial infarction and total mortality: the Copenhagen City Heart Study with 31 years of follow‐up , 2011, Journal of internal medicine.

[18]  M. Banach,et al.  Statins and dilated cardiomyopathy: do we have enough data? , 2011, Expert opinion on investigational drugs.

[19]  R. Berger,et al.  Effects of statin therapy on arrhythmic events and survival in patients with nonischemic dilated cardiomyopathy. , 2006, Journal of the American College of Cardiology.

[20]  Richard B Devereux,et al.  Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardio , 2005, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[21]  R. Collins,et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[22]  L. Tavazzi,et al.  Coronary atherosclerosis in end-stage idiopathic dilated cardiomyopathy: an innocent bystander? , 2005, European heart journal.

[23]  H. Gullu,et al.  Decreased serum lipoprotein levels as a guide for clinical severity in patients with idiopathic dilated cardiomyopathy. , 2005, The Tohoku journal of experimental medicine.

[24]  M. Hori,et al.  Short-Term Statin Therapy Improves Cardiac Function and Symptoms in Patients With Idiopathic Dilated Cardiomyopathy , 2003, Circulation.

[25]  E. Walker Regression Modeling Strategies , 2003, Technometrics.

[26]  Miriam Parker,et al.  Idiopathic dilated cardiomyopathy: a common but mystifying cause of heart failure. , 2002, Cleveland Clinic journal of medicine.

[27]  D. Hosmer,et al.  A comparison of goodness-of-fit tests for the logistic regression model. , 1997, Statistics in medicine.